Although PPARγ can play a role in the treatment of IBD through the crosstalk between metabolism and inflammation [5] and preclinical studies favor a potential usefulness of pioglitazone in the treatment of IBD [2,5], such a benefit of pioglitazone could not be observed in humans in this observational study. This evidence concerns the gene PPARG and inflammatory bowel disease.